Jazz Pharmaceuticals plc’s filing revealed that its SVP, Chief Accounting Officer Carr Patricia unloaded Company’s shares for reported $0.16 million on Mar 10 ’25. In the deal valued at $137.81 per share,1,140 shares were sold. As a result of this transaction, Carr Patricia now holds 7,012 shares worth roughly $0.96 million.
Then, Iannone Robert bought 1,767 shares, generating $256,215 in total proceeds.
Before that, Carr Patricia bought 1,140 shares. Jazz Pharmaceuticals plc shares valued at $157,103 were divested by the Officer at a price of $137.81 per share.
UBS upgraded its Jazz Pharmaceuticals plc [JAZZ] rating to a Buy from a a Neutral in a research note published on March 07, 2025; the price target was increased to $179 from $145. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who decreased its forecast for the stock in late February from “an Overweight” to “a Neutral”. Wells Fargo also remained covering JAZZ and has increased its forecast on February 13, 2025 with a “an Overweight” recommendation from previously “an Equal weight” rating. Morgan Stanley revised its rating on December 12, 2024. It rated JAZZ as “an Overweight” which previously was an “an Equal-weight”.
Price Performance Review of JAZZ
On Tuesday, Jazz Pharmaceuticals plc [NASDAQ:JAZZ] saw its stock fall -0.43% to $136.86. Over the last five days, the stock has lost -1.50%. Jazz Pharmaceuticals plc shares have risen nearly 11.13% since the year began. Nevertheless, the stocks have risen 17.61% over the past one year. While a 52-week high of $148.06 was reached on 02/26/25, a 52-week low of $99.06 was recorded on 01/10/25. SMA at 50 days reached $128.66, while 200 days put it at $116.50.
Levels Of Support And Resistance For JAZZ Stock
The 24-hour chart illustrates a support level at 134.79, which if violated will result in even more drops to 132.72. On the upside, there is a resistance level at 138.76. A further resistance level may holdings at 140.66. The Relative Strength Index (RSI) on the 14-day chart is 54.62, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.50, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 79.65%. Stochastics %K at 28.38% indicates the stock is a holding.
The most recent change occurred on June 05, 2024 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $169 price target.
